Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 3,261,577 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”).
Pete A. Meyers, Chief Financial Officer, has been granted 2,961,577 options to purchase Ordinary Shares which vest over a four year period and are partially based on meeting certain performance targets. Rajesh B. Shukla Ph.D., Vice President of Clinical Operations, was granted 300,000 options to purchase Ordinary Shares which vest over a four year period. The options have an exercise price of 40.50 pence per Ordinary Share, being the closing price of the Ordinary Shares on 21 April 2016, the date of grant of the options.
For further information please contact:
Motif Bio plc
Graham Lumsden (Chief Executive Officer)
info@motifbio.com
Zeus Capital Limited (NOMAD & BROKER)
Phil Walker/Dan Bate
Dominic Wilson
+44 (0)20 3829 5000
Northland Capital Partners Limited (BROKER)
Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking)
+44 (0)20 7382 1100
Walbrook PR Ltd. (FINANCIAL PR & IR)
Paul McManus
Mike Wort +44 (0)20 7933 8780 or motifbio@walbrookpr.com
Mob: +44 (0)7980 541 893
Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN IR)
Raimund Gabriel
+49 (0)89 210 2280
